Clinical Trials

Albireo currently is conducting a Phase 3 clinical trial of investigational product candidate A4250, an ileal bile acid transporter (IBAT) inhibitor that is being studied as a treatment for patients with progressive familial intrahepatic cholestasis (PFIC).

The Phase 3 PFIC program includes a single randomized, double-blind, placebo-controlled, multicenter clinical trial and an open-label long-term extension study. The double-blind trial, called PEDFIC1, is designed to enroll approximately 60 patients with PFIC (subtypes 1 or 2), ages 6 months to 18 years, at sites in the United States, Canada, Europe, the Middle East and Australia.

For more information about the PEDFIC1 study, please visit ClinicalTrials.gov or contact medinfo@albireopharma.com.